AbbVie has been granted a patent for inhibitors targeting the interaction of menin with MLL and MLL fusion proteins, for treating cancer and other diseases. The compound of Formula 0 is the focus of the patent. GlobalData’s report on AbbVie gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on AbbVie, Peptide pharmacophores was a key innovation area identified from patents. AbbVie's grant share as of February 2024 was 47%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent (Publication Number: US11919901B2) discloses a compound of Formula 0, with various specific configurations outlined in the claims. The compound is designed for the treatment of leukemia by minimizing hERG binding, making it potentially effective in inhibiting the interaction between menin and MLL. The patent also covers the use of the compound in pharmaceutical compositions and methods for treating leukemia, including specific types such as mixed lineage leukemia (MLL), acute lymphocytic leukemia (ALL), and acute myeloid leukemia (AML).
Furthermore, the patent extends to the prevention and treatment of diseases associated with menin expression, activity, and function, particularly focusing on leukemia. The compound described in the patent is intended for administering to subjects in need of therapeutic intervention for various forms of leukemia, including those with specific genetic mutations like nucleophosmin (NPM1)-mutated acute myeloid leukemia. The comprehensive scope of the patent encompasses the use of the compound in diverse leukemia subtypes, highlighting its potential impact on different manifestations of the disease and underscoring its relevance in the field of oncology research and treatment.
To know more about GlobalData’s detailed insights on AbbVie, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
